Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 3 , Pages 290-295 , May 2010

Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens

Received 25 June 2008 ,Revised 25 January 2009 ,Accepted 25 January 2009.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Garnick MB. Prostate cancer: Screening, diagnosis, and management. Ann Int Med. 1993;118:804–818
  3. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol. 2006;24:419–424
  4. Tannock IF, de Wit R, Berry WR, et al. Docataxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  6. Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist. 2006;11:451–462
  7. Kiessling A, Füssel S, Wehner R, et al. Advances in specific immunotherapy for prostate cancer. Eur Urol. 2008;53:694–708
  8. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;23:3894–3903
  9. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006;24:434–441
  10. Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells: A phase I/II study. BJU Int. 2004;94:412–418
  11. Abdul M, Hoosein N. Changes in β-2 microglobulin expression in prostate cancer. Urol Oncol. 2000;5:168–172
  12. Valenti MT, Bertold F, Carbonare LD, et al. The effect of biphosphonates on gene expression: GAPDH as a house-keeping or a new target gene?. BMC Cancer. 2006;6:49–55
  13. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138–147
  14. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11–22
  15. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109–1118
  16. Bennett SR, Carbone FR, Karamalis F, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med. 1997;186:65–70
  17. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: Progress in immunotherapy studies for prostate cancer. J Urol. 2004;172:2532–2538
  18. Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother. 2003;52:497–505
  19. Horiguchi Y, Nukaya I, Okazawa K, et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002;8:3885–3892
  20. Peshwa MV, Shi JD, Ruegg C, et al. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate. 1998;36:129–138
  21. Kiessling A, Schmitz M, Stevanovic S, et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer. 2002;102:390–397
  22. Jaffee EM, Lazenby A, Meuer J, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol. 1995;18:1–9
  23. Berard F, Blanco P, Davoust J, et al. Cross-priming of naïve CD8 cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535–1544
  24. Akashi T, Koizumi K, Nagakawa O, et al. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep. 2006;16:831–836
  25. Oikawa T, Kawai K, Ishiwata I, et al. Induction of potent antitumor natural-killer cells from peripheral blood of patients with advanced prostate cancer. BJU Int. 2003;92:1009–1015
  26. Sanda MG, Ayyagari SR, Jaffee EM. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994;151:622–628
  27. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res. 2006;12:3394–3401
  28. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogenic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883–3891

PII: S1078-1439(09)00033-7

doi: 10.1016/j.urolonc.2009.01.029

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 3 , Pages 290-295 , May 2010

Article Tools

* Image Usage & Resolution